Chris Smith is recorded as CEO at QuidelOrtho Corp (QDEL) and CEO and Board Member at Neogenomics Inc (NEO) since August 15, 2022. Neogenomics Inc reported in an 8-K filed January 10, 2025 that Chris Smith retired as board member, effective April 1, 2025. Neogenomics Inc reported in an 8-K filed January 10, 2025 that Chris Smith retired as Chief Executive Officer (CEO) and board member, effective April 1, 2025. Neogenomics Inc reported in an 8-K filed July 21, 2022 that Chris Smith was appointed member of the board of directors, effective August 15, 2022. Equibles holds 4 filed executive changes naming Chris Smith; each is listed under recent activity with its source filing. Chris Smith has spoken on 9 earnings calls across 1 company, most recently for Neogenomics Inc on February 18, 2025. Neogenomics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. QuidelOrtho Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Neogenomics Inc includes Christopher Smith (CEO and Board Member), Tony Zook (CEO, Chairman and Board Member), Warren Stone (CEO, COO and Board Member) and 7 others.
“NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025.”
Neogenomics Inc Form 8-K, filed January 10, 2025
· Read the filing
“NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025.”
Neogenomics Inc Form 8-K, filed January 10, 2025
· Read the filing
Chris Smith on recent calls
“On today's call, we'll discuss the highlights of our fourth quarter and full year financial results and provide an update on key business growth drivers. Before we discuss the financial results, I just want to thank our teammates for their unyielding commitment to our mission and their hard work throughout the year.”
“On today's call, we'll discuss the highlights of our strong second quarter performance and provide an update on the progress made in accelerating profitable revenue growth.”
“Thanks for joining us this afternoon to go through our fourth quarter and full year financial results. As always, I really want to begin with our mission and vision statement because it is what motivates our company and our teammates on a daily basis.”
“As always, I want to begin with our mission, our vision statement because it’s what motivates our company and teammates on a daily basis. Our mission at Neo is to save lives by improving patient care.”
“We like to begin every presentation we do, whether it’s to our teammates, our customers, or investors, with our mission and vision statement because it’s what motivates our company and our teammates on a daily basis.”
